Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

680 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cystosarcoma phyllodes.
LESTER J, STOUT AP. LESTER J, et al. Cancer. 1954 Mar;7(2):335-53. doi: 10.1002/1097-0142(195403)7:2<335::aid-cncr2820070219>3.0.co;2-j. Cancer. 1954. PMID: 13141227 No abstract available.
TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer.
Thomson DJ, Cruickshank C, Baines H, Banner R, Beasley M, Betts G, Bulbeck H, Charlwood F, Christian J, Clarke M, Donnelly O, Foran B, Gillies C, Griffin C, Homer JJ, Langendijk JA, Lee LW, Lester J, Lowe M, McPartlin A, Miles E, Nutting C, Palaniappan N, Prestwich R, Price JM, Roberts C, Roe J, Shanmugasundaram R, Simões R, Thompson A, West C, Wilson L, Wolstenholme J, Hall E. Thomson DJ, et al. Among authors: lester j. Clin Transl Radiat Oncol. 2022 Nov 21;38:147-154. doi: 10.1016/j.ctro.2022.11.010. eCollection 2023 Jan. Clin Transl Radiat Oncol. 2022. PMID: 36452431 Free PMC article.
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.
Phung MT, Webb PM, DeFazio A, Fereday S, Lee AW, Bowtell DDL, Fasching PA, Goode EL, Goodman MT, Karlan BY, Lester J, Matsuo K, Modugno F, Brenton JD, Van Gorp T, Pharoah PDP, Schildkraut JM, McLean K, Meza R, Mukherjee B, Richardson J, Grout B, Chase A, McKinnon Deurloo C, Terry KL, Hanley GE, Pike MC, Berchuck A, Ramus SJ, Pearce CL; Ovarian Cancer Association Consortium. Phung MT, et al. Among authors: lester j. Gynecol Oncol. 2022 Nov 16;168:68-75. doi: 10.1016/j.ygyno.2022.10.018. Online ahead of print. Gynecol Oncol. 2022. PMID: 36401943
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.
Weir A, Kang EY, Meagher NS, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Gentry-Maharaj A, Ryan A, Singh N, Widschwendter M, Alsop J, Anglesio MS, Beckmann MW, Berger J, Bisinotto C, Boros J, Brand AH, Brenton JD, Brooks-Wilson A, Carney ME, Cunningham JM, Cushing-Haugen KL, Cybulski C, Elishaev E, Erber R, Fereday S, Fischer A, Paz-Ares L, Gayarre J, Gilks BC, Grube M, Harnett PR, Harris HR, Hartmann A, Hein A, Hendley J, Hernandez BY, Heublein S, Huang Y, Huzarski T, Jakubowska A, Jimenez-Linan M, Kennedy CJ, Kommoss FKF, Koziak JM, Kraemer B, Le ND, Lesnock J, Lester J, Lubiński J, Menkiszak J, Ney B, Olawaiye A, Orsulic S, Osorio A, Robles-Díaz L, Ruebner M, Shah M, Sharma R, Shvetsov YB, Steed H, Talhouk A, Taylor SE, Traficante N, Vierkant RA, Wang C, Wilkens LR, Winham SJ, Benitez J, Berchuck A, Bowtell DD, Candido Dos Reis FJ, Cook LS, DeFazio A; AOCs group, Doherty JA, Fasching PA, García MJ, Goode EL, Goodman MT, Gronwald J, Huntsman DG, Karlan BY, Kommoss S, Modugno F, Schildkraut JM, Sinn HP, Staebler A, Kelemen LE, Ford CE, Menon U, Pharoah PDP, Köbel M, Ramus SJ. Weir A, et al. Among authors: lester j. Br J Cancer. 2022 Nov 2. doi: 10.1038/s41416-022-02014-y. Online ahead of print. Br J Cancer. 2022. PMID: 36323878
Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes.
Meagher NS, Gorringe KL, Wakefield MJ, Bolithon A, Pang CNI, Chiu DS, Anglesio MS, Mallitt KA, Doherty JA, Harris HR, Schildkraut JM, Berchuck A, Cushing-Haugen KL, Chezar K, Chou A, Tan A, Alsop J, Barlow E, Beckmann MW, Boros J, Bowtell DD, Brand AH, Brenton JD, Campbell I, Cheasley D, Cohen J, Cybulski C, Elishaev E, Erber R, Farrell R, Fischer A, Fu Z, Gilks B, Gill AJ, Gourley C, Grube M, Harnett P, Hartmann A, Hettiaratchi A, Høgdall CK, Huzarski T, Jakubowska A, Jimenez-Linan M, Kennedy CJ, Kim BG, Kim JW, Kim JH, Klett K, Koziak J, Lai T, Laslavic A, Lester J, Leung Y, Li N, Liauw W, Lim BWX, Linder A, Lubinski J, Mahale S, Mateoiu C, McInerny S, Menkiszak J, Minoo P, Mittelstadt S, Morris D, Orsulic S, Park SY, Pearce CL, Pearson JV, Pike MC, Quinn CM, Mohan GR, Rao J, Riggan MJ, Ruebner M, Salfinger S, Scott CL, Shah M, Steed H, Stewart CJR, Subramanian D, Sung S, Tang K, Timpson P, Ward RL, Wiedenhoefer R, Thorne H, Cohen PA, Crowe P, Fasching PA, Gronwald J, Hawkins NJ, Høgdall E, Huntsman DG, James PA, Karlan BY, Kelemen LE, Kommoss S, Konecny GE, Modugno F, Park SK, Staebler A, Sundfeldt K, Wu AH, Talhouk A, Pharoah PDP, Anderson L, DeFazio A, Köbel M, Friedlander ML, Ramus SJ. Meagher NS, et al. Among authors: lester j. Clin Cancer Res. 2022 Oct 12:CCR-22-1206. doi: 10.1158/1078-0432.CCR-22-1206. Online ahead of print. Clin Cancer Res. 2022. PMID: 36222710
Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial.
Fennell DA, Porter C, Lester J, Danson S, Blackhall F, Nicolson M, Nixon L, Gardner G, White A, Griffiths G, Casbard A. Fennell DA, et al. Among authors: lester j. EClinicalMedicine. 2022 Aug 11;52:101595. doi: 10.1016/j.eclinm.2022.101595. eCollection 2022 Oct. EClinicalMedicine. 2022. PMID: 35990583 Free PMC article.
680 results